{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:21:34Z","timestamp":1790738494632,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clgc.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T02:34:38Z","timestamp":1645670078000},"page":"e303-e309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of Renin-Angiotensin System Blockers on BCG Response in Nonmuscle Invasive, High Risk Bladder Cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-589X","authenticated-orcid":false,"given":"Giovanni","family":"Motterle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Morlacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Vecchiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Calpista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Prayer-Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-9276","authenticated-orcid":false,"given":"Francesca","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Dal Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4693-5058","authenticated-orcid":false,"given":"Giacomo","family":"Novara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.02.007_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0002","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0003","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8653489","article-title":"Immunomodulatory effects of drugs for effective cancer immunotherapy","volume":"2018","author":"Matsushita","year":"2018","journal-title":"J Oncol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.02.007_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.11.002","article-title":"Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer","volume":"77","author":"Shirotake","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.02.007_bib0007","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2015.05.104","article-title":"Renin-angiotensin inhibitors decrease recurrence after transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer","volume":"194","author":"Blute","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0008","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","article-title":"Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer","volume":"19","author":"Yuge","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0009","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clgc.2022.02.007_bib0010","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2022.02.007_bib0011","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0012","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2022.02.007_bib0013","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2022.02.007_bib0014","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1245\/s10434-016-5534-3","article-title":"Prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy","volume":"24","author":"Yoshida","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clgc.2022.02.007_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.2011.565","article-title":"Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma","volume":"106","author":"Tanaka","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.02.007_bib0016","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/1078-0432.CCR-05-2213","article-title":"Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer","volume":"12","author":"Kosugi","year":"2006","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"Suppl 3","key":"10.1016\/j.clgc.2022.02.007_bib0017","first-page":"A276","article-title":"Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy","volume":"8","author":"Strauss","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:25Z","timestamp":1761564925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1558767322000441"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.02.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Renin-Angiotensin System Blockers on BCG Response in Nonmuscle Invasive, High Risk Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}